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Abstract 
Background: Metal-on-metal (MOM) hip prostheses have a higher failure rate than conventional 
prostheses, and leaching of cobalt and chromium has been linked to cardiomyopathy.  We screened 
MOM subjects to determine if cobalt and chromium cause subclinical cardiac dysfunction. 
Methods: A single centre, non-randomised, observational study using echocardiography in 95 
patients who had undergone MOM hip prostheses, and 15 age matched controls with non-MOM hip 
replacement.  Serial plasma cobalt and chromium levels were recorded, and data compared by 
tertiles of cobalt exposure.  Results: Indexed left ventricular (LV) end-diastolic and end-systolic 
volumes (EDVi and ESVi) increased with tertile of cobalt (omnibus p=0.003 for EDVi and ESVi), as did 
indexed left atrial (LA) volumes (p=0.003).  MOM subjects had 25% larger EDVi than controls, 32% 
larger ESVi (40ml vs. 32ml, and 15ml vs. 11ml, p=0.003 for both) and 28% larger indexed LA (23ml vs. 
18ml, p=0.002).  There were no differences in LV systolic or diastolic function, including ejection 
fraction, tissue velocity and mitral E/e’.  Estimated glomerular filtration rate was 18% lower in the 
highest tertile compared with the lowest (p=0.01) and correlated inversely with LA volume (r=-0.36, 
p<0.001) and LV EDV (r=-0.24, p=0.02). 
Conclusions: Increasing left ventricular and atrial volumes and declining renal function correlated 
with prolonged exposure to high cobalt, but cardiac function did not.  The association with renal 
function and chamber size requires further evaluation.  Case reports of cardiomyopathy in patients 
with MOM hips imply that an idiosyncratic process cannot be excluded.  
Abstract: 240 words 
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INTRODUCTION 
 
Large head metal-on-metal (MOM) hip replacements were implanted in more than 1 million 
patients between 2003 and 2010.  They were expected to be more durable than conventional metal 
on polyethylene components, and to have a lower risk of dislocation.  In practice, the failure rates 
have been significantly higher.  The bearing surfaces of these prostheses are made from a cobalt- 
chrome alloy, which may be released when the two surfaces slide over one another on hip 
movement.  Over time this leads to elevated plasma levels of cobalt and chromium.  Some patients 
may develop a localised inflammatory reaction around the joint, which can lead to pain and reduced 
mobility.  Others remain asymptomatic despite elevated heavy metal levels in the blood. Revision 
surgery becomes necessary to remove the implant due to local complications, including fluid 
formation, pseudotumours and bone or soft tissue necrosis.  
 
In recent years, reports have emerged of systemic complications associated with high cobalt 
and chromium levels in MOM hip patients, including neurological, psychological, renal, endocrine 
and cardiac disturbances.[1] The Medicines and Healthcare products Regulatory Agency (MHRA) 
have recently reissued a medical device alert regarding MOM hip prostheses, following an initial 
alert in 2010.[2]  This recommends annual review with symptom questionnaire and blood metal 
levels, with imaging depending on the findings of these two screening measures.  Cobalt and 
chromium levels of 7 ug/L or above suggest soft tissue reaction and the MHRA recommend that 
patients with these levels undergo further imaging and investigation. The 2017 update places 
greater emphasis on the role of MRI and ultrasound in decision making. Cardiac and systemic 
screening are not addressed in this guidance.   
 
Toxicity leading to cardiomyopathy has previously been confined to case reports.[3-8]  
Typically, these patients have previously undergone either failed MOM hip replacement or revision 
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of hip arthroplasty; in patients with asymptomatic MOM hip replacements, reports of cardiac 
complications are scarcer.  A review by Bradberry et al found 18 patients identified between 1950 
and 2014 with complications from high cobalt levels derived from hip replacements.[1]  Of these, 11 
had cardiac features, namely left ventricular dysfunction (64%), pericardial effusion (45%) and left 
ventricular dilatation (27%), although a non-dilated cardiomyopathy was seen in several patients.  
 
One patient at our centre presented to the emergency unit with fulminant cardiac failure 
having undergone MOM hip replacement in 2007.  Despite intensive treatment, she died of multi-
organ failure because of severely depressed cardiac function.  There is currently no consensus for 
cardiac screening in patients at risk of this complication.  We therefore performed a cross-sectional 
study of orthopaedic patients who had received MOM hip prostheses to: a) ascertain the prevalence 
of overt cardiomyopathy and b) evaluate any relationship between subclinical markers of cardiac 
dysfunction and levels of plasma cobalt and chromium. 
 
METHODS 
Setting and study population 
This was a single centre, non-randomised, observational study at a tertiary referral centre 
for orthopaedics and for cardiology in south-east Wales.  1698 patients underwent implantation of 
one or more MOM prosthesis within the health board.  We recruited a sample of 95 patients from 
an orthopaedic MOM follow-up clinic between 1st July 2014 and 31st December 2015. All subjects 
with plasma cobalt of 7 ug/L or greater were referred for evaluation. Consecutive subjects with 
plasma levels between 0 and 7 ug/L were screened during clinic appointments and approached if 
they met the recruitment criteria. These patients were recruited on a voluntary basis. Exclusion 
criteria included symptomatic joint dysfunction, previous history of heart failure or prior myocardial 
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infarction. The study cohort included patients with current MOM prostheses as well as those who 
had undergone prosthesis removal.  We also recruited 15 age-and comorbidity-matched control 
subjects from general orthopaedic clinics who had undergone hip replacement with non-MOM 
prostheses according to the same exclusion criteria. A further analysis was performed excluding 
those subjects who had undergone prosthesis explantation to examine whether the effects of high 
cobalt persisted after removal of the heavy metal source.  
 
Power calculations were based on longitudinal deformation velocity (first systolic peak) with 
a mean of the basal septal and basal lateral walls of 7.07 ± 1.65 used as values for normal, healthy 
subjects. [9] A sample size of 95 MOM patients was decided upon as it would have 80% power to 
detect a 20% reduction in longitudinal velocity compared with controls, with a sampling ratio of 15 
control subjects to 95 patients (non-inferiority margin of 0.25).   
For subjects with cobalt and/or chromium >7.0 ug/L at clinic follow-up, the research ethics 
committee (Wales REC 1) concluded that cardiological evaluation was justified on clinical grounds. A 
priori approval from the Research Ethics Committee was granted for the inclusion of subjects with 
cobalt and chromium levels <7.0 ug/L, and for the non-MOM controls in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki (14/WA/1236); both of these groups gave written 
informed consent to participate in this project.  
Data were gathered prospectively from clinic appointments, including baseline 
demographics, height, weight and medication history.  Information regarding operative history and 
serial plasma cobalt and chromium measurements was obtained from the hospital record system.  
Blood was taken for point plasma cobalt and chromium levels, estimated glomerular filtration rate 
(eGFR, MDRD) and serum N-terminal pro-B-type Natriuretic Peptide (NTproBNP) levels when 
patients attended for echocardiography.  
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Cobalt and chromium analysis 
The cobalt and chromium assay used was developed at our laboratory. Five millilitres of 
venous blood were obtained and processed according to  the Trace Elements External Quality 
Assessment Scheme (TEQAS) as per MHRA guidance. Plasma cobalt and chromium levels were 
obtained during the cardiology clinic appointment at which echocardiography was also performed.  
In addition, as most patient had serial measurements, both cobalt and chromium were expressed as 
total dose exposure by calculating the area under the curve of a graph of time against plasma ion 
levels.  Ion levels at the time of prosthesis implantation were approximated as zero.  
 
Echocardiography 
Echocardiography was performed by two experienced, British Society of Echocardiography 
accredited sonographers and reported by a trained clinician (RK) and research sonographer (RL) who 
were blinded to each subject’s plasma metal levels and medical history.  Data were gathered on a 
Vivid-7 (GE Healthcare) echocardiography machine.  Analysis was performed using EchoPAC (Version 
13, GE Healthcare).  A sample of 10 scans was examined by a second, blinded sonographer with 
coefficient of variability of 4.5%.  
Two-dimensional, M-mode, pulse wave and continuous wave Doppler and tissue Doppler 
measurements were taken in accordance with British Society of Echocardiography guidelines.  The 
average value for consecutive three beats was used for calculating echocardiographic parameters. 
Five beats were used where the subject was in atrial fibrillation or had frequent ectopy. Ectopic and 
post-ectopic beats were excluded from analysis.  Left ventricular and left atrial volumes were 
measured using Simpson’s biplane method of discs with end-diastolic and end-systolic frames used 
in the apical four-chamber and apical two-chamber views. Ejection fraction was calculated from left 
ventricular volume measurements. Strain was measured using speckle tracking of the left ventricle 
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by measuring the peak early systolic strain. Global longitudinal strain was calculated as the average 
of six myocardial segments.  
 
Data analysis 
Statistical analysis was performed using SPSS (version 23, IBM).  Normally distributed data 
were expressed using mean ± standard deviation (SD), non-normally distributed data as median ± 
interquartile range and qualitative data as number and percentage.  Analysis was performed using 
the one-way ANOVA for parametric non-ordinal data and the Jonckheere-Terpstra test for all ordinal 
data; this is a non-parametric test used to determine whether there is a statistically significant trend 
between an ordinal independent variable and a continuous or ordinal dependent variable.  
Correlations were assessed using Pearson’s correlation coefficient.  Qualitative data were compared 
using Chi-squared homogeneity test, or Fischer’s Exact Test (using the Freeman-Halton extension) 
where observed counts were less than 5. Where data were missing, analysis was conducted for 
those entries that were present; where data were absent for more than 20% of subjects, data was 
marked as being incomplete. .  
 
RESULTS 
Data were obtained on 95 MOM hip patients (median age: 74.4yrs, 53% male) and 15 
controls (median age: 74.6yrs, 40% male) with non-MOM hip prostheses All patients meeting the 
inclusion and exclusion criteria who had high ion levels agreed to participate, but of the low plasma 
ion group, 17 declined follow-up. 4 non-MOM subjects were unsuitable due to pre-existing heart 
problems.  MOM prosthesis types included Anthology (Smith and Nephew) – 52, ASR (De Puy) – 26, 
Corail/Pinnacle (De Puy) – 9, Cormet (Corin) – 14, Profemur (Wright) – 8 and Trilogy (Zimmer) – 2. In 
three subjects, the prosthesis model was not available from clinical notes.  114 MOM prostheses 
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were used across 95 patients. 19 had received bilateral MOM hips.  18 patients had undergone 
subsequent prosthesis removal, with a median time of 42 days since removal (mean 611 days). 
MOM patients were divided into tertiles according to plasma cobalt levels taken at the 
echocardiography clinic to examine more closely a dose-response relationship between heavy metal 
levels and cardiac findings. Cobalt was chosen as excess of cobalt has historically been demonstrated 
to cause cardiomyopathy whereas chromium has not been causally linked to cardiac problems.[10]  
Baseline characteristics are shown in Table 1.   MOM subjects had undergone a mean of 5.2 plasma 
metal measurements between implantation and study end, the earliest of which was in October 
2009.  
 
There was a strong correlation between plasma cobalt and chromium levels (r=0.78, 
p<0.001), but only a weak correlation between clinic cobalt and cumulative cobalt levels (r=0.31, 
p=0.001).  Clinic and cumulative chromium levels were also weakly related (r=0.38, p<0.001). Plasma 
cobalt was not correlated with age (r=-0.09, p=0.92).  Calcium channel blocker use tended  towards 
being more common than expected in patients compared with controls (p=0.07).  There was no 
other difference in medication use or comorbidity.  Median eGFR decreased with increasing tertile of 
cobalt although no correlation was seen between eGFR and cobalt level (r=-0.14, p=0.14), or  
chromium level (r=-0.10, p=0.28). Cumulative cobalt and chromium were not related to eGFR (r=-
0.04, p=0.71 and r=-0.05, p=0.58, respectively). There was no difference or correlation between 
serum NTproBNP measurements between groups (r=0.03, p=0.74 for cobalt, r=-0.001, p=0.99 for 
chromium).  
Results of echocardiography are given in Table 2.  Left ventricular end-diastolic and end-
systolic volumes, both as absolute values and when indexed for body size, increased with tertile of 
plasma cobalt (Figure 1).  Left atrial size also increased with tertile of cobalt, whereas right 
ventricular sizes were similar.  There was no difference in markers of left and right ventricular 
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systolic function, including longitudinal deformation velocity, ejection fraction; LVOT VTI; MAPSE; 
TAPSE; or strain in the basal septal and basal lateral segments. Diastolic parameters were also 
similar.  These included mitral E and A waves; E/A ratio; mitral E deceleration time; isovolumic 
relaxation time; and medial and lateral e’ velocity on tissue Doppler. Measurement of global 
longitudinal strain was possible in 76  subjects (67%); it was unrelated to cobalt exposure. 
 
All MOM patients were also compared with controls (Tables 1 and 2).  Left atrial volume was 
31% greater in patients than controls and LAVI was 25% greater (p=0.002).  EDV was 32% greater, 
indexed EDV 25%, ESV 41% and indexed ESV 32% greater in patients compared with controls 
(p≤0.002 for all).  Posterior wall thickness was reduced in patients versus controls (mean difference 
1.1mm, p=0.01).  
42 patients had clinic cobalt levels less than the MHRA cut-off of 7 ug/L for device 
dysfunction and 53 had plasma levels more than 7 ug/L. Using this cut-off, EDVi was greater in those 
with high cobalt levels (37.0 ml/m2 vs. 40.0 ml/m2, p=0.03), but ESVi (13.7 vs. 15.0, p=0.30) and LAVi 
(20.6 ml/m2 vs. 23.3 ml/m2, p=0.68) were similar. However, eGFR remained lower in the group with 
the highest cobalt levels (mean rank 66.3 vs. 43.9, p<0.001). There was no difference in systolic or 
diastolic parameters (Vs 4.7 cm/s vs. 4.4 cm/s, p=; EF 63% vs 63%, p=0.82; e’ 7.6 cm/s vs. 7.5 cm/s, 
p=0.78; E/e’ 9.3 vs. 9.3, p=0.78) 
There was a weak inverse correlation between eGFR and left atrial volume (r=-0.39, 
p<0.001Figure 2).  A weak inverse correlation was seen between eGFR and left ventricular end-
diastolic volume (r=-0.24, p=0.02, Figure 2), with a similar correlation that approached significance 
between eGFR and end-systolic volume (r=-0.20, p=0.06).  
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The analyses were repeated excluding subjects who had undergone prosthesis removal. 
There remained a positive association between tertile of clinic cobalt and left ventricular and left 
atrial chamber size: (mean ± SD) EDVi: T1 38.7 ± 6.8 ml/m2, T2 37.7 ± 7.7, T3 42.1 ± 9.1, p=0.003; 
ESVi: T1 14.3 ± 4.1, T2 13.7 ± 4.3, T3 16.1 ± 3.8, p=0.003; LAVi: T1 21.2 ± 7.9, T2 20.3 ± 5.3, T3 26.5 ± 
8.7, p=0.003. A negative association was seen with eGFR (Median T1: 86.1 ± 18.9 μmol/L, T2 83.9 ± 
21.3, T3 70.7 ± 23.3, p=0.007). There was no difference in longitudinal deformation velocity (p=0.22), 
global longitudinal strain (p=0.38), ejection fraction (p=0.14) or diastolic parameters (mitral valve 
E/A (p=0.34) and DT (p=0.07), and tissue Doppler indices (e’ p=0.11; E/e’ p=0.92, IVRT p=0.67). 
Calcium channel blocker use was more common in the highest tertile of cobalt exposure (p=0.02), 
but all other demographics were similar.-= 
 
DISCUSSION 
We found that increased exposure to cobalt was associated with increased heart size.  
Despite this, we observed no difference in sensitive markers of systolic or diastolic left ventricular 
function, or in right ventricular size.  
Several case reports describe patients who presented with dilated cardiomyopathy.  
Typically, the pathophysiology of adverse cardiac remodelling involves initial damage to the 
myocardium which then results in dilatation due to changes in wall tension.  In our study, subjects 
did not have evidence of myocardial dysfunction, suggesting that dilatation may precede the loss of 
myocardial function.  The mechanism for this remains obscure.  Prentice et al compared 35 subjects 
with MOM resurfacing hip replacements with 35 age and sex-matched controls with non-MOM hip 
prostheses.[11]  They found a 6% increase in left ventricular end-diastolic diameter and a 7% 
decrease in ejection fraction.  End-systolic diameter and wall thickness were similar between the 
groups.  These results corroborate our findings, although we did not find a statistically significant 
difference in ejection fraction. There was no difference in the prevalence of comorbidities between 
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patients and controls, or between different tertiles of cobalt, implying that these conditions are not 
causally linked with development of cardiac changes.   
No subjects in this study had enlarged left ventricular volumes.  The chamber size recorded 
in this study is unusually small, with the mean for control subjects being below the normal range. All 
measurements of left ventricular and atrial volumes were conducted by the same researcher.  
Measurements for 10 randomly-chosen scans were repeated by a second blinded operator and were 
in agreement with the first measurements with low inter-observer variability (4.5%).  The trend in 
chamber size was consistent across the patient and control groups, suggesting that the chamber size 
effect is consistent and are still interpretable as a comparison between controls and the three 
patient groups.  
Gillam et al recently found an association between large head ASR prostheses and 
hospitalisation for heart failure in males.  The study found no such links with metal-on-metal 
prostheses in females or with other types of prosthesis.  This was a population study and did not 
investigate markers of cardiac function, however it suggests that there may be more widespread 
links between MOM hip replacements and occult cardiomyopathy. The study population was 
marginally older than in this cohort (median 79 years), and had high levels of comorbidities, with 
55% of them having 4 or more comorbidities.  
No difference in cardiac chamber size was seen between groups when using the standard 
MHRA cut-off of 7 μg/L.  This raises the possibility that the effects of cobalt on visceral organs are 
evident at lower or higher plasma ion levels, and that 7 μg/L is not a sensitive cut-off for detecting 
the difference between these two groups.  Given that the effect found in this study is seen across 
three different measures of cardiac chamber size, it seems unlikely that the results are down to 
probability, but this remains possible.  Berber et al recently looked at the effects of cobalt plasma 
levels on cardiac magnetic resonance imaging as well as multiple echocardiography parameters and 
found no evidence of an effect on cardiac function or chamber size when stratifying groups 
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according to whether they fell above or below the MHRA’s cut-off. [12] The MHRA guidelines were 
developed to indicate the likelihood of joint dysfunction, rather than visceral complications.  In their 
case series, Bradberry et al note that cardiac complications were only evident in those subjects with 
the highest cobalt concentrations. [1] 
Estimated glomerular filtration rate (eGFR) decreased in our cohort with increasing cobalt 
exposure.  This may be due to reduced excretion of cobalt in subjects with reduced renal function; 
alternatively, it could be that deposition of heavy metals in the renal parenchyma causes reduction 
in renal function.  In a study of subjects with end-stage renal disease, it was found that plasma 
chromium and cobalt levels were elevated compared with controls.[13]  It is therefore possible that 
renal dysfunction is the index event which triggers accumulation of cobalt and chromium in these 
patients.  eGFR was moderately correlated with left atrial size and weakly with left ventricular end-
diastolic volume, suggesting that the volume increase may be related to activation of the renin-
angiotensin-aldosterone system rather than cardiotoxicity.  This is supported by the increased 
numbers of subjects on calcium channel blockers in the third tertile, implying treated hypertension 
which may be related to renal disease.  There is a non-significant trend towards more patients with 
atrial fibrillation in the higher tertiles of cobalt compared with controls. It may be that the control 
group is too small to identify a true difference between these groups as the numbers are small. 
Atrial fibrillation is correlated with increased left atrial size and our results would therefore suggests 
that it is aetiologically possible that this condition is associated with increasing plasma cobalt. This 
has not previously been identified in the literature. 
 
It is well recognised that cobalt is deposited within the myocardium when present in high 
levels.[14]   Animal studies demonstrated that contractility of cardiac myocytes is reduced in the 
presence of high cobalt concentrations.[15]  The presence of a pericardial effusion is frequently 
noted in cobalt-related cardiomyopathy.  This is likely to be the cardiac equivalent of the para-joint 
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effusions seen with affected MOM joints and is a sign of generalised inflammation and tissue 
oedema.  A series of patients presenting with cobalt related cardiomyopathy was reported in 1967 in 
subjects without MOM hips who drank beer with cobalt added to stabilise the bubbles in the 
foam.[10]  The clinical picture was of a non-dilated cardiomyopathy associated with pericardial 
effusion that regressed after the additive cobalt was removed from the beer.  At that time, cobalt 
was also given to subjects with anaemia, due to its stimulatory effect on erythropoiesis.  There were 
no reports of cardiomyopathy in the anaemic subjects, suggesting the presence of an additional 
aetiological factor in the development of cardiomyopathy.   
 
Typical histological findings in affected heart tissue in case reports include interstitial 
oedema, myocyte hypertrophy, increased lipofuscin, vacuolation and interstitial fibrosis although 
these findings are not specific to cobalt toxicity and may be found in many causes of 
cardiomyopathy, including dilated, hypertensive and restrictive subtypes.[16]  Abnormal 
mitochondrial appearance is a common, but non-specific finding and tends to be seen in heavy 
metal poisoning.  Nonetheless, the presence of ventricular dysfunction and high plasma cobalt 
levels, especially in the presence of pericardial effusion and polycythaemia, should suggest the 
diagnosis.   
 
MOM hip prostheses are no longer being implanted, and many subjects with high metal ion 
levels have had their devices explanted. The overall population impact of this phenomenon is 
therefore declining. However, individuals remain with the potential for systemic complications and 
clinicians should therefore be aware of the presentation.  
 
Study limitations 
This study was observational and collected limited data on frailty, nutritional status and 
alcohol consumption.  Further studies investigating the link between cobalt and idiosyncratic 
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cardiomyopathy could investigate these cofactors to look for underlying predisposition to 
development of cardiac symptoms.  Biopsies of the myocardium to correlate myocardial heavy metal 
deposition with cardiac findings on echocardiography were not investigated in this study, although 
the index case was shown to have elevated myocardial cobalt and chromium levels at autopsy.  
Confirmation of the link between chamber dilatation and elevated plasma cobalt and chromium 
levels would be aided by corroboration with histological findings in subclinical groups.   
The study was adequately powered to detect differences in systolic function. However, 
analyses were carried out on a number of parameters and therefore may have been subject to 
multiplicity. Other studies have used similar sample sizes, but confirmation of the effects would 
ideally be corroborated by larger studies.  
 
CONCLUSIONS 
Left ventricular and atrial volumes increase with increased plasma cobalt.  However, no evidence of 
systolic or diastolic cardiac dysfunction related to prolonged exposure to high plasma metal ions was 
found in this study.   
 
In view of multiple case reports of fulminant cardiomyopathy in subjects with MOM hip 
prostheses, an idiosyncratic process cannot be excluded. Despite declining patient numbers with 
MOM prostheses and high metal ion levels, clinicians should be aware of the potential for cardiac 
complications and investigate accordingly.  
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FIGURE LEGENDS 
Figure 1:  Effect of increasing tertile of cumulative plasma cobalt levels on: (top panel, left to right) 
left ventricular EDV indexed for body surface area (BSA), ESV indexed for BSA; (middle) left atrial 
volume indexed for body size and estimated glomerular filtration rate; (bottom panel) ejection 
fraction and mean septal and lateral basal systolic Doppler velocities; p values for given pairwise 
comparisons. Mean values given unless otherwise stated. LV = left ventricular.  
Figure 2: Correlation between estimated glomerular filtration rate and (from top) cumulative cobalt 
exposure, left ventricular end-diastolic volume and left atrial volume.  
 
